Evidence map›Paper›PMID 27102317›Full record

SynthesisAJNR. American journal of neuroradiology2016

Endovascular Treatment versus Best Medical Treatment in Patients with Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.

A I Qureshi, M F Ishfaq, H A Rahman, A P Thomas

Open access · hybridAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in AJNR. American journal of neuroradiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Milestones in the history of neurocritical care.Neurological research and practice · 2023
    Review
  3. Changes in Neuroendovascular Procedural Volume During the COVID-19 Pandemic: An International Multicenter Study.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

A I QureshiFrom the Zeenat Qureshi Stroke Institute (A.I.Q., M.F.I.), St. Cloud, Minnesota qureshai@gmail.com.ORCID 0000-0003-0703-7263
M F IshfaqFrom the Zeenat Qureshi Stroke Institute (A.I.Q., M.F.I.), St. Cloud, Minnesota.ORCID 0000-0003-2336-8230
H A RahmanDepartment of Neurology (H.A.R., A.P.T.), Houston Methodist Hospital-Texas Medical Center, Houston, Texas.ORCID 0000-0003-3733-0575
A P ThomasDepartment of Neurology (H.A.R., A.P.T.), Houston Methodist Hospital-Texas Medical Center, Houston, Texas.ORCID 0000-0003-4708-008X
CentraCare Health System · USTexas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeEndovascular treatment has emerged as a minimally invasive technique for patients with acute ischemic stroke to achieve recanalization. Our aim was to determine the effects of endovascular treatment on clinical and safety outcomes compared with best medical treatment. MATERIALS AND

methodsFifteen randomized trials that compared endovascular treatment with best medical treatment in patients with acute ischemic stroke met the inclusion criteria. We calculated pooled odds ratios and 95% CIs by using random-effects models. The primary end point was a favorable outcome defined by a modified Rankin Scale score of 0 (no symptoms), 1 (no significant disability), or 2 (slight disability) at 90 days postrandomization.

resultsOf the 2980 subjects randomized, the proportion of subjects who achieved a favorable outcome was significantly greater among those randomized to endovascular treatment compared with best medical treatment (2949 subjects analyzed; odds ratio, 1.82; 95% CI, 1.38-2.40; P < .001). Excellent outcome (modified Rankin Scale score of 0 or 1) was also significantly greater among those randomized to endovascular treatment (2791 subjects analyzed; odds ratio, 1.77; 95% CI, 1.29-2.43, P < .001). Risk of symptomatic intracranial hemorrhage was similar between endovascular treatment and best medical treatment (2906 subjects analyzed; odds ratio, 1.19; 95% CI, 0.84-1.68; P = .34).

conclusionsCompared with best medical treatment, the odds of achieving a favorable outcome or excellent outcome at 3 months postrandomization are approximately 80% higher with endovascular treatment among patients with acute ischemic stroke.

Indexed as

Brain IschemiaEndovascular ProceduresEndpoint DeterminationHumansRandomized Controlled Trials as TopicStrokeTreatment Outcome

Identifiers

PMID27102317
PMCPMC7963548
OpenAlexW2340728358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.